BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37310241)

  • 21. Impact of a population-based colorectal cancer screening program on local health services demand in Italy: a 7-year survey in a northern province.
    Parente F; Marino B; Ardizzoia A; Ucci G; Ilardo A; Limonta F; Villani P; Moretti R; Zucchi A; Cremaschini M; Pirola ME
    Am J Gastroenterol; 2011 Nov; 106(11):1986-93. PubMed ID: 21670773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physician-office vs home uptake of colorectal cancer screening using FOBT/FIT among screening-eligible US adults.
    Chido-Amajuoyi OG; Sharma A; Talluri R; Tami-Maury I; Shete S
    Cancer Med; 2019 Dec; 8(17):7408-7418. PubMed ID: 31637870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
    Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
    BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Colon Cancer Screening - Is It Time Yet?
    Bhurgri H; Samiullah S
    J Coll Physicians Surg Pak; 2017 Jun; 27(6):327-328. PubMed ID: 28689518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Model-Based Estimation of Colorectal Cancer Screening and Outcomes During the COVID-19 Pandemic.
    Issaka RB; Taylor P; Baxi A; Inadomi JM; Ramsey SD; Roth J
    JAMA Netw Open; 2021 Apr; 4(4):e216454. PubMed ID: 33843997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies.
    Inadomi JM; Vijan S; Janz NK; Fagerlin A; Thomas JP; Lin YV; Muñoz R; Lau C; Somsouk M; El-Nachef N; Hayward RA
    Arch Intern Med; 2012 Apr; 172(7):575-82. PubMed ID: 22493463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of Screening Using Fecal Occult Blood Testing and Colonoscopy on the Risk of Colorectal Cancer: The Japan Public Health Center-based Prospective Study.
    Tanaka K; Sobue T; Zha L; Kitamura T; Sawada N; Iwasaki M; Inoue M; Yamaji T; Tsugane S
    J Epidemiol; 2023 Feb; 33(2):91-100. PubMed ID: 34053963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Participant-Related Risk Factors for False-Positive and False-Negative Fecal Immunochemical Tests in Colorectal Cancer Screening: Systematic Review and Meta-Analysis.
    de Klerk CM; Vendrig LM; Bossuyt PM; Dekker E
    Am J Gastroenterol; 2018 Dec; 113(12):1778-1787. PubMed ID: 30158713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effectiveness of a multifaceted intervention to improve adherence to annual colorectal cancer screening in community health centers: a randomized clinical trial.
    Baker DW; Brown T; Buchanan DR; Weil J; Balsley K; Ranalli L; Lee JY; Cameron KA; Ferreira MR; Stephens Q; Goldman SN; Rademaker A; Wolf MS
    JAMA Intern Med; 2014 Aug; 174(8):1235-41. PubMed ID: 24934845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study.
    van Wifferen F; de Jonge L; Worthington J; Greuter MJE; Lew JB; Nadeau C; van den Puttelaar R; Feletto E; Yong JHE; Lansdorp-Vogelaar I; Canfell K; Coupé VMH;
    J Med Screen; 2022 Jun; 29(2):72-83. PubMed ID: 35100894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Évaluation de la gravité du cancer colorectal dépisté dans le contexte de la crise sanitaire liée au COVID19 en région Ile-de-France].
    Koïvogui A; Abihsera G; Le Trong T; Ait-Hadad H; Bernoux A; Delattre H; Vincelet C; Caroll R; Nicolet J
    Rev Epidemiol Sante Publique; 2023 Oct; 71(5):102124. PubMed ID: 37451076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies.
    Sharaf RN; Ladabaum U
    Am J Gastroenterol; 2013 Jan; 108(1):120-32. PubMed ID: 23247579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Colorectal Cancer Screening with Mailed Fecal Immunochemical Tests and Telephone Outreach at a Community Health Center during the COVID-19 Pandemic.
    Ritzenthaler D; Deshpande S; Ryan M; Daprano J
    J Health Care Poor Underserved; 2022; 33(2):973-983. PubMed ID: 35574888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial.
    Gupta S; Halm EA; Rockey DC; Hammons M; Koch M; Carter E; Valdez L; Tong L; Ahn C; Kashner M; Argenbright K; Tiro J; Geng Z; Pruitt S; Skinner CS
    JAMA Intern Med; 2013 Oct; 173(18):1725-32. PubMed ID: 23921906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contribution of patient, physician, and environmental factors to demographic and health variation in colonoscopy follow-up for abnormal colorectal cancer screening test results.
    Partin MR; Gravely AA; Burgess JF; Haggstrom DA; Lillie SE; Nelson DB; Nugent SM; Shaukat A; Sultan S; Walter LC; Burgess DJ
    Cancer; 2017 Sep; 123(18):3502-3512. PubMed ID: 28493543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modelling optimal use of temporarily restricted colonoscopy capacity in a FIT-based CRC screening program: Application during the COVID-19 pandemic.
    de Jonge L; van de Schootbrugge-Vandermeer HJ; Breekveldt ECH; Spaander MCW; van Vuuren HJ; van Kemenade FJ; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    PLoS One; 2022; 17(6):e0270223. PubMed ID: 35749423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COVID-19 and inequities in colorectal and cervical cancer screening and diagnosis in Washington State.
    Amram O; Amiri S; Robison J; Pflugeisen CM; Monsivais P
    Cancer Med; 2022 Aug; 11(15):2990-2998. PubMed ID: 35304835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal Adherence to Immunochemical Fecal Occult Blood Testing vs Guaiac-based FOBT in an Organized Colorectal Cancer Screening Program.
    Benito L; Travier N; Binefa G; Vidal C; Espinosa J; Milà N; Garcia M
    Cancer Prev Res (Phila); 2019 May; 12(5):327-334. PubMed ID: 30890542
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.